The Scientist

» biotechnology and disease/medicine

Most Recent

image: Pharma Cooperates to Achieve Precision Medicine

Pharma Cooperates to Achieve Precision Medicine

By | February 1, 2017

The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.

0 Comments

image: May the Force Be with You

May the Force Be with You

By | February 1, 2017

The dissection of how cells sense and propagate physical forces is leading to exciting new tools and discoveries in mechanobiology and mechanomedicine.

5 Comments

image: Opinion: Preparing for Potential Disasters

Opinion: Preparing for Potential Disasters

By | January 25, 2017

How to increase the resiliency of biotechnology organizations in the face of emergency risks

0 Comments

image: Exploring the Epigenetics of Ethnicity

Exploring the Epigenetics of Ethnicity

By | January 11, 2017

Researchers attempt to estimate how much of the human genome’s methylation patterns can be attributed to genetic ancestry.

0 Comments

image: Drug Approval Timeline Same as 20 Years Ago

Drug Approval Timeline Same as 20 Years Ago

By | January 9, 2017

A report finds that new medications still take about 12 years to go from patent to patient.

0 Comments

image: Contributors

Contributors

By | January 1, 2017

Meet some of the people featured in the January 2017 issue of The Scientist.

0 Comments

image: Pharma Redo

Pharma Redo

By | January 1, 2017

Steve Braun of Cures Within Reach, a nonprofit focused on breathing new life into old medicines, describes the potential benefits of drug repurposing.

1 Comment

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

0 Comments

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

0 Comments

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

Popular Now

  1. Decoding the Tripping Brain
  2. Tattoo Ink Nanoparticles Persist in Lymph Nodes
    The Nutshell Tattoo Ink Nanoparticles Persist in Lymph Nodes

    Analysis of the bodies of deceased individuals can’t determine what effect these tattoo remnants have on lymph function, but researchers suggest dirty needles aren’t the only risk of the age-old practice.

  3. Do Microbes Trigger Alzheimer’s Disease?
  4. Metabolomics Data Under Scrutiny
    Daily News Metabolomics Data Under Scrutiny

    Out of 25,000 features originally detected by metabolic profiling of E. coli, fewer than 1,000 represent unique metabolites, a study finds.

AAAS